Therapies Targeting Mucosal Eosinophils in Eosinophilic Gut Diseases From Esophagus to Colon
Journal of Gastroenterology and Hepatology · 2026
DOI: 10.1111/jgh.70221 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Gastroenterology and Hepatology, 2026. Verfasst von Khaliun Batkhurel und 5 weiteren Autor:innen. Beteiligte Einrichtung: NHMRC Centre of Research Excellence in Transforming Gut Health, University of Newcastle, Newcastle, New South Wales, Australia. Hauptthemen laut MEDLINE: Eosinophilia, Eosinophils, Eosinophilic Esophagitis, Gastritis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 197 Literaturangaben. Gefördert von: National Health and Medical Research Council.
Abstract (Originalsprache)
Eosinophilic gastrointestinal disorders (EGIDs) comprise eosinophilic oesophagitis (EoE) and non‐EoE EGIDs; these diseases may be increasing in prevalence and are likely underdiagnosed. Mortality is not increased in EoE but is in gastric and small intestinal EGIDs. A subtle increase in eosinophils has also been observed in other GI diseases including functional dyspepsia in the duodenum. Targeted drug therapy can markedly reduce eosinophil infiltration, although symptom response is more variable, suggesting that non–eosinophil pathways play a role in pathogenesis. Current standard therapies for EoE supported by randomized trials include proton pump inhibitors, corticosteroids (topical), diet restriction, and dupilumab, inhibiting IL‐4/IL‐13 signaling. In non‐EoE EGIDs where little randomized trial data exist, management is based on a combination of dietary elimination and corticosteroids or immunomodulators; mast cell stabilizers and antihistamine therapy may have a role. The role of combination therapies is unclear. Pharmacologic approaches in testing include new steroid preparations and delivery systems; dupilumab in eosinophilic gastritis; and anti‐IL‐13, anti‐IL‐5, anti‐IL‐2, and anti‐IL‐15 receptor targeting monoclonal antibodies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- NHMRC Centre of Research Excellence in Transforming Gut Health, University of Newcastle, Newcastle, New South Wales, Australia.
- John Hunter Hospital, Lambton, New South Wales, Australia.
- Hunter Medical Research Institute, Newcastle, New South Wales, Australia.
- Centre for Drug Repurposing and Medicines Research, University of Newcastle, Newcastle, New South Wales, Australia.
ORCID-Profile: Sharmila Prasad, Simon Keely, Nicholas J Talley
Förderung
- National Health and Medical Research Council
Zitieren
APA
Batkhurel, K., Prasad, S., Potter, M., Martin, J. H., Keely, S., & Talley, N. J. (2026). Therapies Targeting Mucosal Eosinophils in Eosinophilic Gut Diseases From Esophagus to Colon. Journal of Gastroenterology and Hepatology. https://doi.org/10.1111/jgh.70221
Vancouver
Batkhurel K, Prasad S, Potter M, Martin JH, Keely S, Talley NJ. Therapies Targeting Mucosal Eosinophils in Eosinophilic Gut Diseases From Esophagus to Colon. Journal of Gastroenterology and Hepatology. 2026. doi:10.1111/jgh.70221
BibTeX
@article{Batkhurel2026,
author = {Batkhurel, Khaliun and Prasad, Sharmila and Potter, Michael and Martin, Jennifer H and Keely, Simon and Talley, Nicholas J},
title = {Therapies Targeting Mucosal Eosinophils in Eosinophilic Gut Diseases From Esophagus to Colon},
journal = {Journal of Gastroenterology and Hepatology},
year = {2026},
doi = {10.1111/jgh.70221}
}
EUVIMED